REGENXBIO to Pay $10M to GSK to Settle Sublicense Fee Dispute
Summary
REGENXBIO Inc. will make a $10.0 million payment to GlaxoSmithKline LLC to settle a dispute regarding sublicense fees, impacting the company's cash position amidst ongoing financial concerns.
Key Events
-
Settlement Agreement Reached
REGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC (GSK) on March 18, 2026, to resolve a non-binding mediation related to a 2009 License Agreement.
-
Mandatory $10 Million Payment
The company will make a $10.0 million payment to GSK within three business days of the effective date for alleged underpayment of sublicense fees.
-
Mutual Release of Claims
The Settlement Agreement includes mutual releases of all past claims and certain specified types of future claims arising from the GSK-REGENXBIO Sublicense.
Analysis
REGENXBIO has agreed to pay GlaxoSmithKline LLC (GSK) $10.0 million to resolve a long-standing dispute over sublicense fees. This payment, representing a material cash outflow for the company, comes at a critical time given REGENXBIO's previously disclosed substantial doubt about its ability to continue as a going concern and recent FDA setbacks. While the settlement resolves past and certain future claims, the immediate financial impact is negative, reducing the company's cash runway.
At the time of this filing, RGNX was trading at $8.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $418.1M. The 52-week trading range was $5.04 to $16.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.